COMMUNIQUÉS West-GlobeNewswire

American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on Tuesday, June 25, 2024
21/05/2024
Meeting Will be Held at The Hilton Hotel, San Francisco, CA SAN FRANCISCO, May 21, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey [...]
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
21/05/2024
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits colitis disease progression and colon inflammation, lowers inflammatory mucosal cytokines, and reduces expression of IBD-associated genes in a colitis [...]
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
21/05/2024
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024 Received $7.0 million clinical development milestone from Pfizer for PF-08046052 [...]
Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services
21/05/2024
VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical [...]
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
21/05/2024
Translational data presented during a late-breaker poster session from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD indicates that eblasakimab performed better than dupilumab in [...]
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
21/05/2024
WINSTON-SALEM, N.C., May 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), [...]
Kincell Bio Announces New Board Chairman Mark R. Bamforth to Accelerate Company’s Growth and Expansion
21/05/2024
Serial entrepreneur has created, built and sold three CDMOs GAINESVILLE, Fla., May 21, 2024 (GLOBE NEWSWIRE) -- Kincell Bio, LLC (“Kincell”), a technology-forward contract development and manufacturing organization ( [...]
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
21/05/2024
NEW HAVEN, Conn., May 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno- [...]
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
21/05/2024
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem [...]
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
21/05/2024
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at the American [...]
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates
21/05/2024
Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025 Company will host a conference call and [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 avril 2024
21/05/2024
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 avril 2024 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, les [...]
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences
21/05/2024
LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM [...]
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
21/05/2024
Planegg/Martinsried, May 21, 2024 . Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T cell [...]
CancerVax Successfully Uses Nobel Prize Chemistry to Achieve Universal Cancer Vaccine Targeting Milestone
21/05/2024
The UCLA research team created a low cost and customizable lipid nanoparticle using “click chemistry” for precise targeting of cancer cell surface markers Santa Barbara, May 21, 2024 (GLOBE NEWSWIRE) -- Santa Barbara, [...]
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
21/05/2024
Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, May 21, 2024 . Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to [...]
Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA
21/05/2024
Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA Paris, New York, New York et San Francisco, Californie, 21 mai 2024. Sanofi, Formation Bio et OpenAI collaborent afin de [...]
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
21/05/2024
Saint-Herblain (France), May 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (CSO) [...]
Valneva annonce la nomination du Dr Hanneke Schuitemaker en tant que Directeur Scientifique
21/05/2024
Saint-Herblain (France), le 21 mai 2024 – Valneva SE (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui la nomination du Dr Hanneke Schuitemaker, Ph.D. en tant que [...]

Pages